J. Safra Sarasin Holding AG Lowers Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Key Points

• J. Safra Sarasin Holding AG has significantly reduced its stake in Regeneron Pharmaceuticals by 68% during the first quarter, now owning 1,000 shares valued at approximately $634,000.
• Regeneron's recent quarterly earnings report showed an EPS of $12.89, surpassing estimates, with a revenue of $3.68 billion, reflecting a 3.6% year-over-year increase.
• The company has announced a quarterly dividend of $0.88, which is set to yield an annualized 0.6% and highlights its low dividend payout ratio of 8.87%.

J. Safra Sarasin Holding AG lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 68.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,000 shares of the biopharmaceutical company's stock after selling 2,125 shares during the quarter. J. Safra Sarasin Holding AG's holdings in Regeneron Pharmaceuticals were worth $634,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in the company. Bank of Nova Scotia lifted its holdings in shares of Regeneron Pharmaceuticals by 36.0% during the first quarter. Bank of Nova Scotia now owns 122,589 shares of the biopharmaceutical company's stock worth $77,750,000 after purchasing an additional 32,427 shares during the period. Banco Santander S.A. increased its stake in shares of Regeneron Pharmaceuticals by 58.5% in the first quarter. Banco Santander S.A. now owns 11,852 shares of the biopharmaceutical company's stock worth $7,517,000 after acquiring an additional 4,374 shares during the period. OVERSEA CHINESE BANKING Corp Ltd purchased a new position in shares of Regeneron Pharmaceuticals during the first quarter worth $30,168,000. TIAA Trust National Association boosted its holdings in Regeneron Pharmaceuticals by 1,187.4% in the first quarter. TIAA Trust National Association now owns 26,018 shares of the biopharmaceutical company's stock valued at $16,501,000 after purchasing an additional 23,997 shares during the last quarter. Finally, UNIVEST FINANCIAL Corp grew its position in Regeneron Pharmaceuticals by 29.7% during the 1st quarter. UNIVEST FINANCIAL Corp now owns 18,419 shares of the biopharmaceutical company's stock worth $11,682,000 after purchasing an additional 4,217 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN traded down $14.77 during mid-day trading on Wednesday, hitting $555.13. 864,754 shares of the company were exchanged, compared to its average volume of 969,242. The company has a quick ratio of 4.73, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. The firm has a market cap of $59.93 billion, a price-to-earnings ratio of 13.99, a price-to-earnings-growth ratio of 2.08 and a beta of 0.33. The stock has a 50 day simple moving average of $537.05 and a 200-day simple moving average of $601.77. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%. The company had revenue of $3,675,600 billion for the quarter, compared to analyst estimates of $3.30 billion. During the same quarter in the previous year, the company earned $11.56 EPS. The firm's revenue for the quarter was up 3.6% compared to the same quarter last year. On average, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Monday, August 18th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Monday, August 18th. Regeneron Pharmaceuticals's payout ratio is currently 8.87%.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Argus downgraded Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday, June 30th. Wall Street Zen cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 1st. Guggenheim increased their price target on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a "buy" rating in a report on Friday, August 1st. UBS Group reaffirmed a "neutral" rating on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Finally, Morgan Stanley increased their target price on shares of Regeneron Pharmaceuticals from $754.00 to $761.00 and gave the stock an "overweight" rating in a research note on Friday, August 1st. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $841.30.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.